Description
The abstract explicitly states that despite evidence connecting GM dysbiosis and AD progression, the involvement of GM in modulating microglia-mediated neuroinflammation remains elusive. Understanding these mechanisms is critical for developing targeted therapeutic interventions for AD.
Gap type: open_question Source paper: Microglia and gut microbiota: A double-edged sword in Alzheimer’s disease. (None, None, PMID:39321881)
Resolution criteria
Resolved when gut microbiota effects on AD microglial neuroinflammation are traced to specific taxa, metabolites, or immune pathways. Required evidence: germ-free or antibiotic-treated AD models colonized with defined microbiota, microglial single-cell profiling, metabolomics such as SCFA/bile acid/tryptophan products, cytokine and complement readouts, amyloid/tau pathology, and rescue with candidate metabolites or receptor knockouts. Closure requires a reproducible microbiota-to-microglia mechanism that alters AD pathology.